Tech Company Financing Transactions

Zogenix Funding Round

On 7/14/2010, Zogenix announced $50 million in funding from Chicago Growth Partners, Clarus and Domain Associates.

Transaction Overview

Company Name
Announced On
7/14/2010
Transaction Type
Debt
Venture Equity
Amount
$50,000,000
Round
Undisclosed
Investors

Chicago Growth Partners (Arda Minocherhomjee)

Clarus (Kurt Wheeler)

Domain Associates (James Blair)

Scale Venture Partners (Louis Bock)

Thomas, McNerny & Partners (Alexander Zisson)

Proceeds Purpose
The financing will be used to satisfy working capital needs in the commercial launch of SUMAVEL´┐Ż DosePro´┐Ż (sumatriptan injection) needle-free delivery system, the company's first FDA-approved product, and the ongoing Phase 3 clinical development program of ZX002, a novel oral controlled-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain. Proceeds will also be used to fully repay the outstanding balance of an existing term loan.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
5858 Horton St. 455
Emeryville, CA 94608
USA
Email Address
Overview
Zogenix (NASDAQ: ZGNX) is a specialty pharmaceutical company whose goal is to uniquely enhance and differentiate medicines by incorporating innovative technologies in an effort to relieve suffering in people with CNS and pain disorders.
Profile
Zogenix LinkedIn Company Profile
Social Media
Zogenix Company Twitter Account
Company News
Zogenix News
Facebook
Zogenix on Facebook
YouTube
Zogenix on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Stephen Farr
  Stephen Farr LinkedIn Profile  Stephen Farr Twitter Account  Stephen Farr News  Stephen Farr on Facebook
Chief Financial Officer
Michael Smith
  Michael Smith LinkedIn Profile  Michael Smith Twitter Account  Michael Smith News  Michael Smith on Facebook
Chief Medical Officer
Bradley Galer
  Bradley Galer LinkedIn Profile  Bradley Galer Twitter Account  Bradley Galer News  Bradley Galer on Facebook
VP - Bus. Development
Gail Farfel
  Gail Farfel LinkedIn Profile  Gail Farfel Twitter Account  Gail Farfel News  Gail Farfel on Facebook
VP - Bus. Development
Ashish Sagrolikar
  Ashish Sagrolikar LinkedIn Profile  Ashish Sagrolikar Twitter Account  Ashish Sagrolikar News  Ashish Sagrolikar on Facebook


 

 

Browse more venture capital transactions:

Prev: 7/14/2010: RF Code venture capital transaction
Next: 7/14/2010: Morphlabs venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary